Roche’s Tecentriq Receives FDA Priority Review for Stage III Colon Cancer
BASEL, Switzerland, June 11, 2026 Roche has announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
inflammatory disease
Advertisement
DKSH and BridgeBio Partner to Expand ATTR-CM Treatment Access
SINGAPORE, June 11, 2026 DKSH Healthcare and BridgeBio have entered into a strategic distribution and commercialization partnership aimed at...
Takeda’s Zasocitinib Outperforms Deucravacitinib in Psoriasis
STOCKHOLM, Sweden, June 11OSAKA, Japan and CAMBRIDGE, Massachusetts, June 11, 2026, 2026 Takeda has announced positive topline results from...
Formation Bio Doses First Participant in Phase 1 Trial of BLKR201, a CNS-Penetrant TYK2 Inhibitor
NEW YORK, June 9, 2026 Formation Bio announced the first participant has been dosed in a Phase 1 first-in-human...
Antengene Presents First Preclinical Data for ATG-207 at EULAR 2026
SHANGHAI and HONG KONG, China, June 8, 2026 Antengene Corporation Limited announced the presentation of the first preclinical data...
Advertisements
Immunic Presents New Phase 2 Data Supporting Vidofludimus Calcium in Progressive MS
NEW YORK, May 28, 2026 Immunic, Inc. has unveiled new analyses from its Phase 2 CALLIPER trial evaluating vidofludimus...
Johnson & Johnson Wins FDA Label Expansion for TREMFYA
HORSHAM, Pennsylvania, May 28, 2026 Johnson & Johnson has secured a major regulatory milestone after the U.S. Food and...
Apogee Therapeutics Lands $1.3B Blackstone Deal
SAN FRANCISCO and BOSTON, May 27, 2026 Apogee Therapeutics announced a landmark $1.3 billion strategic financing collaboration with Blackstone...
Apogee to Reveal Phase 2 Zumilokibart AD Data
SAN FRANCISCO and BOSTON, May 26, 2026 Apogee Therapeutics announced it will report Part B 16-week clinical data from...
InflaRx Secures INN “Izicopan” for Oral C5aR Inhibitor INF904
JENA, Germany, December 11, 2025 — InflaRx N.V. announced that the World Health Organization (WHO) has granted the International...
Advertisement
